Europe Telmisartan Market By Indication (Hypertension and Cardiovascular Risk Reduction), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies), By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Telmisartan Market
Market Report Description
The Europe Telmisartan Market would witness market growth of 5.4% CAGR during the forecast period (2020-2026). Telmisartan refers to a group of antihypertensive drugs known as angiotensin receptor blockers (ARBs). Using this medication, hypertension (high blood pressure) can be managed & treated.
It operates by restricting the action of some substances that constrict the blood vessels, allowing the smooth blood flow & the heart to pump more effectively. Telmisartan is also utilized in reducing the possibility of stroke, heart attack, or death in persons 55 years of age or older who are more prone to cardiovascular diseases. Telmisartan comes as a tablet to be consumed by mouth. Telmisartan drug could be utilized alone or combined with other drugs like amlodipine & hydrochlorothiazide. There are three different forms of this tablet.
There is a common & new term attached with lifestyle i.e. sedentary. Due to hectic lifestyles and air-conditioned work environments of corporates, the requirement for people to remain active has decreased considerably. All these factors are likely to increase lifestyle diseases such as diabetes, cardiovascular, and hypertension diseases. While low physical activity will enhance the possibilities of the disease, the increasing population choosing bad habits such as smoking and alcohol with an aim to relax the nerves would increase the cases of cardiovascular diseases. Telmisartan is utilized in the treatment of all these mentioned conditions. With the rising number of patients, consumption of telmisartan is anticipated to witness a hike during the forecast period.
The Germany market dominated the Europe Online Pharmacies Market by Country in 2019, thereby, achieving a market value of $24 million by 2026. The UK market is exhibiting a CAGR of 5% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 7.4% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments Covered in the Report:
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free